The resulting cellular product is intended to present multiple cancer-associated signals to the immune system rather than relying on a single target. The vaccine platform was previously investigated in a clinical trial for glioblastoma, the most common primary malignant brain tumor in adults. The launch reflects a broader shift toward personalized immunotherapy, in which a patient’s tumor is used to generate treatment-specific molecular information. “Our immune system has the hardware to attack and kill cancer cells,” Georges said. Subject of Research: PeopleArticle Title: Personalized Dendritic-Cell Vaccine Enters Clinical Trial for Treatment-Resistant Advanced MelanomaNews Publication Date: Aug. 11, 2026Web References: www.honorhealthresearch.orgReferences: HonorHealth Research Institute; Diakonos Oncology; “Dendritic Cell Immunotherapy for Refractory Melanoma” clinical trialKeywords: melanoma, advanced melanoma, cancer immunotherapy, dendritic cells, DOC1021, dubodencel, personalized cancer vaccine, mRNA, tumor proteins, clinical trial, metastatic cancer, refractory cancer, HonorHealth Research Institute